Table 1.
Baseline characteristics of the study cohort (n = 245).
| Characteristics | N (%) |
|---|---|
| Age (years) | |
| Median (range) | 62 (29–81) |
| Primary site | |
| Tubo-ovarian | 216/245 (88.2) |
| Peritoneal | 29/245 (11.8) |
| FIGO stage | |
| III | 105/245 (42.9) |
| IV | 125/245 (51.0) |
| Advanced, not otherwise specified | 15/245 (6.1) |
| BRCA status (n = 127) | |
| BRCA positive | 28/127 (22.0) |
| BRCA negative | 99/127 (78.0) |
| Cycles of NACT | |
| 3 or 4 | 168/245 (68.6) |
| >4 | 75/245 (30.6) |
| Unknown | 2/245 (0.8) |
| Total of ≥6 cycles of chemotherapy | |
| Neoadjuvant+adjuvant | 194/245 (79.2) |
| Regimen of NACT | |
| Carboplatin/paclitaxel only | 217/245 (88.6) |
| Carboplatin/paclitaxel and additional agent(s) | 17/245 (6.9) |
| Platinum-based therapy (no paclitaxel) | 11/245 (4.5) |
| Scored site | |
| Omentum | 101/245 (41.2) |
| Adnexa | 144/245 (58.8) |
| Follow-up (months) | |
| Median (range) | 27 (5–160) |